Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Observational, Prospective, Multicenter, Open-label Study to Monitor the Evolution of Myasthenia Gravis Symptoms in Real-life in Patients With Anti-AChR and Anti-MUSK Generalised Myasthenia Gravis in Therapy With RYSTIGGO® (Rozanolixizumab)

NCT07570589 is registered in ClinicalTrials.gov with Centre Hospitalier Universitaire de Nice as lead sponsor.

NCT NCT07570589
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07570589 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Observational, Prospective, Multicenter, Open-label Study to Monitor the Evolution of Myasthenia Gravis Symptoms in Real-life in Patients With Anti-AChR and Anti-MUSK Generalised Myasthenia Gravis in Therapy With RYSTIGGO® (Rozanolixizumab)
Lead sponsor
Centre Hospitalier Universitaire de Nice
Phase
Observational
Overall status
Recruiting
Start date
June 15, 2026
Completion date
March 31, 2028
Enrollment
50 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

generalized myasthenia gravis